Loading clinical trials...

RECRUITINGNA

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

NCT06335914•University Health Network, Toronto

Summary

This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Male, age ≥ 18 years
•Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
•Poor risk patients with mCSPC at study enrollment
•De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
•High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
•Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
•No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study

Exclusion Criteria

•Under a randomized-controlled trial with unknown allocation of systemic therapy
•Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
•Unable to provide written consent by patient and their legal representatives
•In the opinion of the treating physician:
•conditions which would significantly impair the patient's ability to comply with study procedures and follow up
•Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
•* another active malignancy
•* patient on dialysis
•* another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging

Locations (1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Key Dates

Start Date

April 3, 2025

Primary Completion Date

March 4, 2029

Completion Date

September 4, 2029

Last Updated

February 12, 2026

Enrollment

ESTIMATED participants

Conditions

Advanced Prostate Cancer

Interventions

Ga 68 PSMA-11 PET

DIAGNOSTIC_TEST

18F-DCFPyL PET

DIAGNOSTIC_TEST

FDG PET

DIAGNOSTIC_TEST

Contacts

Di (Maria) Jiang, M.D.

CONTACT

416-946-4501 di.jiang@uhn.ca

Whole Body MRI in Oncology

NCT06895291

LymphomaAdvanced Prostate Cancer+4 more

View study

RECRUITINGPHASE2

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

NCT05406999

Neoadjuvant TherapyHigh Risk Prostate Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Inclusion Criteria

Exclusion Criteria

Whole Body MRI in Oncology

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

MRI Guided Transurethral HIFU for Various Prostate Diseases